Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by Lynx9on Feb 19, 2018 2:29pm
134 Views
Post# 27583761

RE:RE:RE:Promis presentation by dr goldstein

RE:RE:RE:Promis presentation by dr goldsteinWill there be a ROLLBACK? - YES. But until the market makers can stablize the market price and volume of sellers it will be awhile. Nasdeq requires that a price of US$4 is stablized in order to list and not based on earnings. So, depending on how the market goes over the next few months will determine the roll back amount. There will need to be a good varience as many will sell right after a roll back as they stablize the price of PMS. At near 300 million share fully diluted and the existing price range you can expect a 10 - 15 for one roll back. News will be important to help stablize the price and volume sold so unless that happens spec writers can and will write what they want to suck new holder into the stock at higher prices. I believe something is being set up, now it's all about timing and deep pockets!
Bullboard Posts